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functioning may become one of the most important clinical
targets in the treatment of schizophrenia.
PMH47
WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY
DURING TREATMENT OF SCHIZOPHRENIA WITH
ANTIPSYCHOTICS AND WITH PLACEBO
Ascher-Svanum H, Stensland MD, Kinon BJ,Tollefson GD
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OBJECTIVE: To investigate if a) the previously observed link
between weight gain and better clinical response during treat-
ment of schizophrenia has a non-pharmacological component,
and b) if the magnitude of treatment-related weight gain paral-
lels therapeutic effect size across different treatments.
METHODS: We compared olanzapine (N = 187) and placebo
(N = 61) during the ﬁrst 6 weeks of a randomized double-blind
trial in the treatment of schizophrenia. Pearson correlations
assessed the association between weight change and therapeutic
response as measured by BPRS total score. Weight change within
treatment group was contrasted between patients who improved
and those who deteriorated. Analyses were repeated controlling
for treatment duration and baseline weight. RESULTS: Weight
gain was signiﬁcantly correlated with better therapeutic response
for placebo (r = 0.36, p = 0.004) and olanzapine-treated patients
(r = 0.43, p = 0.001). Improved patients gained signiﬁcantly more
weight than patients who deteriorated (p = 0.0001). After 
controlling for treatment duration and baseline weight, every 
1-point improvement on BPRS was associated with 0.056kg
weight gain for olanzapine and 0.089kg weight gain for placebo.
The correlation between therapeutic effect size, per Cochrane’s
meta-analytical reviews, and previously published magnitude of
the corresponding treatment’s weight gain (clozapine, olanzap-
ine, risperidone, haloperidol, placebo) was high and signiﬁcant
(r = 0.91, p = 0.03). CONCLUSIONS: An association between
improvement in psychopathology and greater weight gain was
observed in schizophrenia patients treated with olanzapine and
placebo. Findings suggest that treatment-related weight gain has,
in part, a non-pharmacological basis. Further studies are needed
to evaluate the hypothesis that weight gain, regardless of treat-
ment, is associated with improving psychopathology in schizo-
phrenia patients.
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OBJECTIVES: Evaluation of HRQOL has gained increasing
importance in assessing the impact of mental health policies and
the introduction of new neuroleptic drugs. Quetiapine, a new
antipsychotic medication with improved effectiveness, safety and
tolerability proﬁle was introduced in Greece in 2001. The objec-
tive of this study is to assess the HRQOL impact of quetiapine-
based treatment to patients with schizophrenia using a combined
set of outcome measures based on a) psychopathology, b)
HRQOL proﬁles and c) disability scales. METHODS: An open
label, 52-week follow–up study of 170 patients is being con-
ducted in 8 psychiatric hospitals across Greece. Enrolled patients
were diagnosed with mild to moderate schizophrenia (according
to the DSM-IV), aged 18–65, hospitalized or outpatients, newly
diagnosed or in acute exacerbation and assessed at 4 scheduled
visits (baseline, 3-6-12 months). Outcome measures employed
combine psychopathology scales (PANSS, CGI), HRQOL pro-
ﬁles (SF-36, EQ-5D, QLS) and disability indices (WHO-DAS).
All measures are psychometrically and culturally adapted. The
results of 6-month follow-up period are presented in this analy-
sis. RESULTS: Compared to baseline, statistically signiﬁcant
improvements were seen at 6 months in PANSS general psy-
chopathology (48.6 vs. 33.3), positive (23.8 vs.15.2) and nega-
tive symptom (24.3 vs. 17.8) mean scores (p < 0.001). CGI scores
improved from mean level of 5,1 (baseline) to 4,1 (p < 0.001).
All SF-36 dimension scores, especially Role Physical and Role
Emotional were signiﬁcantly improved (p < 0.001). All EQ-5D
dimensions were improved but only the mobility dimension 
and VAS scores showed statistically signiﬁcant improvement 
(p < 0.001). Total and subscale QLS scores were signiﬁcantly
improved except the Instrumental Role Subscale Score (p <
0.001). A statistically signiﬁcant improvement was shown on all
WHO-DAS-II dimensions (p < 0.001). CONCLUSIONS: After
6 months follow-up, quetiapine-treated patients showed a con-
siderable, signiﬁcant improvement in terms of psychopathology
and HRQOL. The combined approach provides for a compre-
hensive assessment of HRQOL impact of new antipsychotic
medications.
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OBJECTIVES: Since end-users of surveys may have design
format preferences that are undetected by survey
developer/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-related
quality of life survey for community-residing individuals with
schizophrenia. METHODS: Using cognitive interviews and
visual analogue preference ratings (0–100 scale), we sought 
qualitative and quantitative input from 29 community-residing
clients with schizophrenia and 33 staff members at four sites con-
cerning their preferences for three formats of the 51-item Schiz-
ophrenia Outcomes Assessment Project (SOAP-51) Survey: (i)
6-page booklet with reponses horizontally listed below each
item, (ii) 4-page version with reponses to the right of each item,
and (iii) compressed 2-page version of the former. Survey formats
were presented in randomized order. Staff alsowere asked their
preference for a 4 vs 5 response format. Clients were individu-
ally interviewed in 15–20 minute sessions; staff had individual
(20–30 minute) or group (45–60 minute) sessions. RESULTS:
Clients preferred versions (i) and (ii) over version (iii); respective
VAS values of 70.1, 68.9, and 47.0 (p = 0.012). Qualitatively,
clients indicated the 2-page was too compressed and the 4-page
format made it easier to link the response to the question. Staff
preferred 4/item responses to 5 (84.0 vs 46.1, p < 0.0001)
because they perceived little distinction between 2 of the 5
response levels. Staff had a preference trend toward version (ii)
compared to versions (i) and (iii), 68.6, 58.6, and 58.9, respec-
tively, p = 0.22. When asked their ﬁrst choice, 47%, 34%, and
19% indicated preference for 4-page, 2-page, and booklet ver-
sions, respectively. CONCLUSIONS: Clients preferred booklet
